Patent · US Active

Combination of DR5 agonist and anti-PD-1 antagonist and methods of use

US11103579B2 · kind B2 · utility

0Cited by
33References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 31, 2018
Grant dateAug 31, 2021
Priority date—
Expiry dateNov 1, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/569
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist in combination with a DR4 or DR5 agonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.